[Medical significance of endothelial glycocalyx. Part 2: Its role in vascular diseases and in diabetic complications].
Level 5 - mechanism / opinion, no new human data
Narrative review detailing mechanisms without systematic search criteria or primary data synthesis.
PubMed 24836779 · doi:10.1016/j.acmx.2013.10.006
What was done
This narrative review synthesized literature on the structure and pathophysiological role of the endothelial glycocalyx in vascular diseases. It evaluated the impact of vascular risk factors—such as hypercholesterolemia, hyperglycemia, inflammation, salt excess, and altered shear stress—on glycocalyx degradation across atherosclerosis, diabetic microangiopathy, and chronic venous disease, as well as the therapeutic effects of sulodexide.
What was found
The abstract reports no numerical or quantitative data. Mechanistically, glycocalyx shedding enables low-density lipoprotein and leukocyte infiltration into the subendothelial space during atherogenesis, permits albuminuria and microvascular injury via oxidative stress in diabetes, and drives leukocyte migration and venous inflammation under altered shear stress. Treatment with sulodexide is reported to prevent or restore glycocalyx damage, improve chronic venous disease, promote venous ulcer healing, and show utility in peripheral arterial disease and diabetic nephropathy.
Why it matters
The paper frames endothelial glycocalyx degradation as a unifying mechanism across diverse arterial, venous, and microvascular pathologies, highlighting glycocalyx-protective therapies as potential multi-disease interventions.
Limits
The abstract provides no quantitative metrics, effect sizes, sample sizes, or systematic review methodology. As a narrative overview, findings are purely descriptive and derived from secondary literature without risk of bias evaluation.
Cited by
- supports Repeated glucose and insulin spikes wear down and damage the endothelial glycocalyx lining of artery walls, initiating plaque formation.